Retirement Systems of Alabama made a bold financial move by increasing its stake in Regeneron Pharmaceuticals by a whopping ...

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Regeneron Pharmaceuticals Inc. stock grades by Barron's. View REGN fundamental and sentiment analysis powered by MarketGrader.

Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently conducted its Annual General Meeting, resulting in approved changes to its company bylaws. The amendments, along with the promising results from the ...